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Abstract: Background ― Antiretroviral (ARV) therapy has successfully reduced the transmission, morbidity, and mortality of Human 
immunodeficiency virus 1 (HIV-1) infection, but the appearance of drug resistance mutations (DRMs) is an obstacle to successful HIV 
management. DRMs against nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) have never been analyzed and reported in HIV-1 patients in Padang (West Sumatra, Indonesia). 
Objective ― This study aimed to identify NRTI- and NNRTI-DRMs from HIV-1 proviral deoxyribonucleic acid (DNA) in HIV-infected patients 
who had received ARV therapy for >12 months at the Dr. M. Djamil General Hospital in Padang. 
Material and Methods ― We isolated HIV-1 proviral DNA from blood samples from 105 HIV-1 patients who had undergone first-line ARV 
therapy for >12 months. Isolates were amplified via a nested PCR technique using two primer-specific types of reverse transcriptase (RT). 
The amplicon was electrophoresed on 0.8% agarose gel and then sequenced. Analysis of DRMs in the HIV-1 RT genes was based on the 
Standford HIV database. 
Results ― The 17 isolates from 105 ARV-treated patients, eight RT genes were successfully sequenced, and DRM of RT inhibitors was found 
in one of the isolates (12.5%). The Stanford HIV database analysis detected three new DRMs at the 184th, 215th and 190th codon 
positions, causing three mutations: M184L and T215N (NRTI-DRMs) with low-level resistance to zidovudine, and G190D (NNRTI-DRM). 
Conclusion ― We concluded that the new DRMs found in Padang, West Sumatra indicates the importance of genotypic resistance testing 
and the periodic evaluation of the effectiveness of ARV drugs currently in use. 
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Introduction  
The provision of highly active antiretroviral treatment (HAART) 
may decrease the transmission, morbidity, and mortality of Human 
immunodeficiency virus 1 (HIV-1) infection due to its ability to 
suppress the virus to undetectable levels. Long-term use of 
HAART, however, leads to drug-selective immune pressure in the 
HIV-1 population. This selective pressure causes mutations of the 
viral peptide as it attempts to escape the host immune system. 
The virus that escapes the immune system is a mutant strain that 
possesses better replication and viral fitness capacity, which may 
lead to the accumulation of mutations [1]. 
The accumulation of mutations during targeted therapy has 
led to the emergence of drug resistance mutations (DRMs). DRMs 
are suspected to cause treatment failure and immune system 
reconstitution failure, allowing the disease to progress rapidly 
[2, 3]. 
Information concerning DRM in Indonesia is very limited, and 
DRMs have not been analyzed and reported in people with HIV-1 
in Padang, West Sumatra, Indonesia. The study by Khairunnisa et 
al. [3] in Surabaya reported that 53 reverse transcriptases (RT) 
sequences from 66 HIV-infected persons who had received HAART 
for more than two years identified a major DRM genetic strain of 
37.7% (20/53). This high prevalence of DRM is a marker of the 
need for periodic evaluation of the effectiveness of HAART use in 
Indonesia. 
The number of HIV cases in Indonesia tripled between 2001 
and 2009, and the virus is now found in all provinces in Indonesia 
(in 2004, it was only reported in 11 provinces). Cumulatively 
between 1 April 1987 and 30 September 2014, there were 150,296 
HIV-positive cases, 55,799 cases of acquired immune deficiency 
syndrome (AIDS), and 9,796 HIV-related deaths. This prevalence is 
likely to be greater due to the large number of HIV/AIDS sufferers 
who do not report themselves [4]. 
The Indonesian provinces with the highest prevalence of AIDS 
cases per 100,000 people are Papua (359.43/100,000), West 
Papua (228.03/100,000), Bali (109.52/100,000), and DKI Jakarta 
(77.82/100,000). West Sumatra is ranked 14
th
, with a prevalence 
19.64/100,000 [4]. Based on data from the Ministry of Health 
Republic of Indonesia in 2015, there were 1,136 HIV patients in 
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West Sumatra as of September 2014. Padang City has the second 
highest prevalence of HIV/AIDS after Bukittinggi. 
The increased number of HIV cases in Indonesia led to the 
government's launch of the HAART expansion program in 2004. 
The first-line antiretroviral (ARV) typically recommended in 
Indonesia is a combination of two nucleoside reverse transcriptase 
inhibitor (NRTI) groups and a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) group. NRTI-class ARVs include zidovudine (AZT), 
tenofovir (TDF), lamivudine (3TC), and emtricitabine (FTC), 
whereas NNRTI-class ARVs are nevirapine (NVP) and efavirenz 
(EFV). A combination of protease inhibitors (PPIs) with 
lopinavir/ritonavir (LPV/r) and two classes of NRTIs is the second-
line ARV recommended for people with HIV who manifest 
virological failure or toxicity to NNRTIs [5]. 
Based on the background described above, this study aimed to 
detect DRM in HIV-1 patients aged >18 years who had been using 
first-line HAART for more than one year at the Dr. M. Djamil 
General Hospital in Padang, West Sumatra. The present study was 
the first study in West Sumatra to identify DRM against HAART. 
 
Material and Methods 
Demographic characteristics of the research subjects  
Demographic characteristics were obtained from the patients’ 
medical records. A total of 105 HIV-1 patients aged >18 years who 
had received first-line HAART for more than 12 months had blood 
drawn by trained phlebotomists at Poli Voluntary Counseling 
Testing. 
 
Isolation of HIV-1 proviral deoxyribonucleic acid 
After blood samples were obtained from HIV patients, HIV-1 
proviral deoxyribonucleic acid (DNA) was extracted from 2 mL 
whole blood in ethylenediaminetetraacetate and the number of 
CD4 T-cells was examined in the Central Laboratory at the Dr. M. 
Djamil General Hospital in Padang. Extraction was conducted using 
the genome PureLink DNA kit (Invitrogen). The work procedure 
was in accordance with the recommended protocols of the kit, 
consisting of 1) blood thinning, 2) DNA binding, 3) DNA leaching, 
and 4) DNA elution. The extraction results were electrophoresed 
to ensure the success of the isolation procedure. 
 
Amplification via nested polymerase chain reaction technique 
Amplification was performed on the RT gene, via two stages of 
amplification. In Stage, I, the DNA template of HIV-1 DNA was 
proviral DNA. The primers used were HIV-RT1-R (5'-GGA CTA CAG 
TCY ACT TGT CCA TG-3') and HIV-RT1-F (5'-ATG ATA GGG ATG GGA 
ATG GGT TT-3'), which was added to a PCR master Mix 
(Invitrogen). Amplification was performed over 30 cycles of 
polymerase chain reaction (PCR), with each cycle consisting of 
initial denaturation at 92ºC for 10 minutes, further denaturation at 
92ºC for 30 minutes, annealing at 55ºC for 30 minutes, extension 
at 72ºC for 45 minutes, and further extension at 72ºC for 5 
minutes. In Stage II, the template DNA was the PCR product from 
Stage I, the primers used were HIV-RT2-R (5'-TTA AAA TCA CTA 
RCC ATT GYT CTC C-3') and HIV-RT2-F (5'-GAC CTA CAC CTG TCA 
ACA TAA TTG G-3'), and the same PCR master mix (Invitrogen) was 
used. Amplification was conducted for 30 cycles using the same 
PCR settings are those used in Stage I. 
 
Electrophoresis of PCR products 
Electrophoresis of nested PCR products was performed using a 
0.8% agarose gel and cyber green colorant. Electrophoresis was 
set to 100 volts for 40 minutes, and results were measured using 
UV light. 
 
Sequencing and DRM analysis  
Sequencing was conducted at 1st Base Singapore. The 
sequencing results were analyzed to identify mutations and amino 
acid changes in the RT gene. The sequence was aligned with 
CLUSTAL-W software version 1.81 and edited using BioEdit 
sequence editor version 7.0.4. The type and position of mutations 
and amino acid changes were determined by comparison to a 
reference sequence. The sequence was uploaded to the Stanford 
University HIV Drug Resistance Database to obtain a DRM profile. 
 
Results 
A total of 80 research subjects (76.2%) were men, 48.6% were 
aged 30–39 years and 52.4% were married (Table 1). The highest 
level of education of the respondents was high school or 
equivalent (50.5%), and 70.5% of research subjects had a job. Most 
of the risk factors for HIV-1 infection/transmission possibility were 
heterosexual (67.6%). Co-infection was found in 22 (21.0%) 
subjects, with the highest co-infection being hepatitis B. A total of 
57 (55.3%) subjects were at an advanced stage (stage 3). 
The most common ARV regimens used by the study subjects 
were AZT+3TC+NVP (54.4%) and TDF+3TC+EFV (40.8%). Patients 
receiving second-line ARVs were not found in this study. 
A total of 105 proviral DNA isolates were amplified and 
electrophoresed, but only 17 samples showed clear bands. These 
17 isolates (amplicons) were sequenced, but only eight RT 
sequences could be analyzed. The Stanford HIV database analysis 
found one DRM in the eight RT sequences (DRM prevalence = 
12.5%), showing three new DRMs at the 184
th
, 215
th
, and 190
th
 
codon positions. These DRMs were M184L and T215N (DRMs for 
NRTI) with low-level resistance to AZT, and G190D (DRM for 
NNRTI), respectively. 
 
 
Table 1. Demographic characteristics of research subjects (n=105) 
Characteristics no. (%) 
Gender: 
- Male 
- Female 
 
80 (76.2) 
25 (23.8) 
Age, years old: 
20-29  
30-39  
40-49 
50-59  
 
35 (33.3) 
51 (48.6) 
11 (10.5) 
8 (7.6) 
Marital status: 
- Married 
- Single 
 
55 (52.4) 
50 (47.6) 
Education: 
- SD (Elementary School) 
- SMP (Junior High School) 
- SMA (Senior High School) 
- College 
 
8 (7.6) 
19 (18.1) 
53 (50.5) 
25 (23.8) 
Job status: 
- Working 
- Unemployment 
 
74 (70.5) 
31 (29.5) 
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Discussion 
HIV-1 proviral DNA is a more stable genetic material than viral 
RNA and can be extracted from the buffy coat, whole blood, or 
peripheral blood mononuclear cells. HIV-1 proviral DNA also 
provides a greater probability of outcome against DRM analysis 
despite a low viral load (<50 copies/mL), due to the persistence of 
DRM in CD4 T cell memory [6, 7]. 
The success of the nested PCR and HIV-1 proviral DNA 
sequencing in this study was low, as only 17 samples showed bands 
on electrophoresis and the sequencing results showed only eight RT 
sequences that could be analyzed. Failure of the amplification of 
proviral HIV-1 DNA is most likely due to the high level of genetic 
variability of HIV-1, keeping the primer from sticking to the DNA 
template. The broad genetic variability of HIV-1 in different 
geographical regions of the world is caused by 1) error-prone RT-
induced mutation, 2) recombination occurring during viral 
replication, 3) high rates of replication and viral turnover, and 4) 
diversification of viruses against immune selective pressure, 
including drug selective pressure due to long-term use of HAART [8-
10].  
Aghokeng et al. also reported changes in the success of several 
genotyping-based diagnostic methods due to the predominant 
genetic variation of HIV-1 sequences in Africa [11]. For instance, 
failure of the ViroSeq HIV-1 genotyping system amplified and 
interfered with some non-B variants in Cameroon that had high 
levels of HIV-1 variability. The use of degenerative primers is 
expected to amplify the success of proviral amplification of HIV-1 
DNA. 
Based on the results of this study, one DRM was obtained from 
eight isolates of RT, meaning that the prevalence of DRM was 
12.5%. Meanwhile, the other seven isolates of RT revealed the 
only variation of RT mutations that were unrelated to resistance to 
ARV. Data concerning DRM in Indonesia remain very limited. 
Khairunisa et al. conducted a DRM analysis of 66 HIV-1 patients 
who had used HAART for more than two years in Surabaya and 
found a 37.7% DRM prevalence. In contrast, Trotter et al. stated 
that the incidence of HIV DRMs in South and East Africa is 
estimated to have increased by 15% and 30% per year since 
HAART was first used [5]. 
DRM is based on rapid viral evolution and high levels of genetic 
variability in HIV-1 [1, 12-14]. Long-term ARV therapy results in 
drug selective immune pressure on the HIV-1 population, which 
causes mutations of viral peptides as the virus attempts to escape 
the host immune system. Viruses that escape the immune system 
are HIV-1 mutant strains, continuing the infection and replicating 
the host cells/CD4 T-cells to accumulate mutations suspected to 
cause DRM [1]. 
The DRMs found in this study were M184L and T215N (NRTI 
DRMs), and G190D (NNRTI DRM). Analysis of the Standford HIV 
database showed that the DRMs M184L and T215N elicited a low 
level of resistance to AZT in the subject while remaining sensitive 
to other NRTI classes. In contrast, the DRM G190D remained 
sensitive to all NNRTI groups. The DRMs of NRTIs at codons 184 
and 215 observed in this study was also found in studies by 
Khairunisa et al. and Kotaki et al., but in both of those studies, the 
amino acid methionine was replaced by valine (M184V), not by 
leucine, and threonine was replaced by tyrosine (T215Y) and 
phenylalanine (T215F), not by asparagine (T215N) [3, 15]. 
Mutations involving threonine are known as thymidine analog 
mutations (TAM). Based on the literature, other mutations in the 
TAM position are often found; for example, the threonine at 
codon 215 (T215) can be replaced by amino acids other than 
phenylalanine (F), such as tyrosine (Y), cysteine (C), aspartic acid 
(D), glutamic acid (E), isoleucine (I), serine (S), or valine (V) 
(T215F/Y/C/D/E/I/S/V) [14]. In contrast, the current study found 
that threonine was replaced by asparagine (T215N). An NNRTI 
DRM at codon 190 was also found by Khairunisa et al., but in their 
study, the glycine in this position was replaced by alanine (G190A), 
not by aspartic acid (G190D). Kotaki et al. (2015) found no 
mutations in codon 190 [3, 15]. 
The novelty of this study’s DRM results is also reinforced by 
previous data showing that 98.8–99.0% of HIV-infected persons on 
ARVs were found to possess specific M184V, K65R, K103N, V106M, 
Y181C, and G190A mutations [16, 17]. In contrast, the current 
study found a mutation at codon 184 where methionine was 
replaced by leucine (M184L), not by valine, and another mutation 
at codon 190 where glycine was replaced by aspartic acid (G190D), 
not by alanine. 
In summary, the new DRMs found in Padang, West Sumatra 
indicates the importance of genotypic resistance testing and 
periodic evaluation of the effectiveness of ARV drugs currently in 
use. Further studies using greater sample sizes, as well as 
degenerative primers to improve amplification and sequencing 
success, are needed, however. 
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